文献速递肝胆胰外科围术期管理与 ERAS

新辅助化疗时代胰瘘与长期生存的关联

Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
PubMed 文献 · JAMA Surg · 2019-01-01

该回顾性队列研究纳入2007至2017年753例胰腺导管腺癌切除患者,比较新辅助治疗与直接手术的术后并发症及总生存。新辅助治疗与临床相关术后胰瘘(CR-POPF)发生率降低相关,但一旦发生CR-POPF则与更差的总生存独立相关。

要点

  • 新辅助治疗后CR-POPF发生率较直接手术降低3.6倍。
  • 新辅助治疗后仅软胰腺质地与CR-POPF风险升高相关。
  • 新辅助治疗后发生CR-POPF者总生存显著更差。

核心结论

  • 新辅助治疗可能与CR-POPF发生率显著降低相关,但一旦发生CR-POPF则与长期生存显著缩短独立相关。

主要发现

  • 新辅助治疗组与直接手术组严重并发症率和90天死亡率无显著差异。
  • CR-POPF发生率在新辅助治疗组为3.8%(13例),直接手术组为13.8%(56例),P < .001。
  • 新辅助治疗后仅软胰腺质地与CR-POPF风险升高相关(38.5% vs 6.3%;P < .001)。
  • 直接手术组有无CR-POPF的总生存无差异(26 vs 25个月;P = .66)。
  • 新辅助治疗组发生CR-POPF者总生存更差(17 vs 34个月;P = .002),多因素分析风险比2.80(95%CI 1.44-5.45;P < .002)。

临床怎么用

  • 新辅助治疗后可沿用软胰腺质地评估CR-POPF风险,但传统危险因素可能不再适用。
  • 新辅助治疗后发生CR-POPF的患者可能需要更密切随访并考虑额外治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the past decade, the use of neoadjuvant therapy (NAT) has increased for patients with borderline and locally advanced pancreatic ductal adenocarcinoma (PDAC). Data on pancreatic fistula and related overall survival (OS) in this setting are limited. OBJECTIVE: To compare postoperative complications in patients undergoing either upfront resection or pancreatectomy following NAT, focusing on clinically relevant postoperative pancreatic fistula (CR-POPF) and potential associations with OS. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted on data from patients who underwent pancreatic resection for PDAC at the Massachusetts General Hospital from January 1, 2007, to December 31, 2017. EXPOSURES: Pancreatic cancer surgery with or without NAT. MAIN OUTCOMES AND MEASURES: Overall morbidity and CR-POPF rates were compared between NAT and upfront resection. Factors associated with CR-POPF were assessed with univariate and multivariate analysis. Survival data were analyzed by Kaplan-Meier curves and a Cox proportional hazards regression model. RESULTS: Of 753 patients, 364 were men (48.3%); median (interquartile range) age was 68 (61-75) years. A total of 346 patients (45.9%) received NAT and 407 patients (54.1%) underwent upfront resection. At pathologic examination, NAT was associated with smaller tumor size (mean [SD], 26.0 [15.3] mm vs 32.7 [14.4] mm; P < .001), reduced nodal involvement (102 [25.1%] vs 191 [55.2%]; P < .001), and higher R0 rates (257 [74.3%] vs 239 [58.7%]; P < .001). There were no significant differences in severe complication rate or 90-day mortality. The rate of CR-POPF was 3.6-fold lower in patients receiving NAT vs upfront resection (13 [3.8%] vs 56 [13.8%]; P < .001). In addition, factors associated with CR-POPF changed after NAT, and only soft pancreatic texture was associated with a higher risk of CR-POPF (38.5% vs 6.3%; P < .001). Survival analysis showed no differences between patients with or without CR-POPF after upfront resection (26 vs 25 months; P = .66), but after NAT, a worse overall survival rate was observed in patients with CR-POPF (17 vs 34 months; P = .002). This association was independent of other established predictors of overall survival by multivariate analysis (hazard ratio, 2.80; 95% CI, 1.44-5.45; P < .002). CONCLUSIONS AND RELEVANCE: Neoadjuvant therapy may be associated with a significant reduction in the rate of CR-POPF. In addition, standard factors associated with CR-POPF appear to be no longer applicable following NAT. However, once CR-POPF occurs, it is associated with a significant reduction in long-term survival. Patients with CR-POPF may require closer follow-up and could benefit from additional therapy.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Hank T, Sandini M, Ferrone CR, et al. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. JAMA Surg. 2019. PMID: 31411659. doi:10.1001/jamasurg.2019.2272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。